Michael Beckenstein, MD
Plastic and Reconstructive Surgery · Birmingham, ALNPI 1356323547
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $9,707 of the $10,363 with a category attached, or 93.7%. AbbVie accounts for 99.7% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2021 at $2,416 and has fallen 59.6% since, to $976 in 2025. Among plastic and reconstructive surgery clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 86 payments — averaging $120.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$10K
- Boston Scientific$16
- Kowa Pharmaceuticals America, Inc.$14
What the payments were for
- Speaking & faculty fees$9,70794%
- Food & beverage$6566%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 84 | $10,333 |
| Boston Scientific | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NATRELLE$106
How this compares
$10,363 in reported general payments places this provider in the 90th percentile of 35 plastic and reconstructive surgery providers in Alabama.
See all plastic and reconstructive surgery providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Montelukast Sodium | 15 | $325 |
| Ondansetron Hcl | 31 | $241 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 22 | $206 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 34 | $168 |
| Methocarbamol | 42 | $148 |
| Cephalexin | 41 | $123 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 28 | $105 |
| Ciprofloxacin Hcl | 18 | $82 |
Paid to pharmacies, not to this prescriber.
Other plastic and reconstructive surgery in Birmingham
- Brad DenneyBirmingham$21K
- Robert OliverBirmingham$7K
- Paul SauerBirmingham$6K
- Jonathan AntonettiBirmingham$4K
- Richard FixBirmingham$2K
- Jorge de la TorreBirmingham$1K
- William RifkinBirmingham$1K
- Alexandre PrassinosBirmingham$885
- Luis VasconezBirmingham$160
- John GrantBirmingham$52
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.